

## PRS Account: Roles and Responsibilities

3


### **PRS Roles and Terms**

- Administrator: maintains PRS Account for organization (may be more than one)
- User: creates and edits records (unlimited number per PRS Account)
- Record Owner: primary contact for study record (may be Admin or User)
- Responsible Party: Sponsor\* (Admin) or Principal Investigator (User)

\* For Sponsor definition see: <a href="https://prsinfo.clinicaltrials.gov/ElaborationsOnDefinitions.pdf">https://prsinfo.clinicaltrials.gov/ElaborationsOnDefinitions.pdf</a>


### **PRS Administrator**

- Maintains PRS Account for organization
  - Creates/disables Users within account
  - Has access to all study records
    - · Can grant Users access to any study record
  - Monitors records in account for "Problems"
    - Use Record List to identify records with Problems; work with Users to resolve Problems
    - Email is sent to Admin, generally every 6 months, notifying of Problems with records in their account at that time
  - Approves and Releases records when the Organization is the Sponsor <u>and</u> Responsible Party
    - Email is sent to Admin when a record is ready for Approval and Release




### **PRS User**


- · Creates and edits records
  - Only has access to records in which they are the Record Owner or on the Access List
  - Approves and Releases records when a Sponsor-Investigator or Principal Investigator is the Responsible Party




### **PRS Record Owner**

- Primary contact for study record
  - Initially assigned to person who created the study record; record ownership can be transferred (by Admin)
  - Can grant other Users access to the record
  - Receives email communications about record
    - · Automatically signed up to receive email; can't opt out
    - Responsible Party will also receive emails (if not Record Owner)










# PRS Account Management


























# PRS: Study Record Basics



# Items To Consider Before Registering a Protocol

- Each protocol can only be registered once
  - Avoid duplicate registrations (i.e., multiple records for same study)
    - · Agree on the Sponsor and the Responsible Party ahead of time
    - Multisite studies are NOT registered by each individual site
    - Multi-collaborator/funder studies need to designate a single entity to register the study
- Studies must be registered by the Responsible Party (study Sponsor or designated Principal Investigator [PI])


http://prsinfo.clinicaltrials.gov/fdaaa.html


### **Data Elements**


- · Data elements: pull-down menus or free text
  - Required\*
  - Optional (Note: some are needed for FDAAA)
    - Indicated as FDAAA required and (FDAAA) may be required
  - Conditionally required<sup>[\*]</sup>
    - · If provide optional item, all related information must be entered
- ClinicalTrials.gov > Submit Studies > Support Materials: https://clinicaltrials.gov/ct2/manage-recs/resources
  - Protocol Data Element Definitions (DRAFT)
  - "Basic Results" Data Element Definitions (DRAFT)
  - Simple Results Templates & Data Preparation Checklists
    - · Overview of tabular format and additional explanation of data needed

27

### **Data Element Definitions in PRS During data entry** Clinical Trials. gov PRS Ora: PRSTrainingMaster User, RJW Protocol Registration and Results System Home > Record Summary > Protocol Section > Study Status Parallel Study Design Example (With Results [NCT ID not yet assigned **Edit Study Status** Help Definitions \* ‡ Record Verification Date: December • Year: 2011 \* ‡ Overall Recruitment Status: Completed ‡ Study Start Date: March • Year: 2010 Year: 2011 Type: Actual \* ‡ Primary Completion Date: August Study Completion Date: August gust • Year: 2011 Type: Actual Final data collection date for study. \* Required by ClinicalTrials.gov ‡ = FDAAA Required to comply with US FDA Amendments Act (1) = (FDAAA) May be required to comply with US FDA Amendments Act 28








### **Trials Registered with NCI's CTRP**


- Not automatically registered with ClinicalTrials.gov
- Upload Protocol Information from CTRP to PRS (access from PRS Main Menu > XML Upload)
- Information needed:
  - NCI Record ID
  - Unique Protocol ID
  - CTRP Username and Password
- Recommended Uses:
  - Create a new study record
  - Update locations in an existing study record





### **PRS Validation Rules**

 A record must have <u>no Errors</u> in order for it to be submitted for posting on ClinicalTrials.gov

Туре	Explanation
ERROR	Problems that must be addressed (e.g., missing required* content, internal inconsistency)
▲ WARNING	Items that are FDAAA <u>required</u> or (FDAAA) <u>may be required</u> (e.g., Study Start Date data element)
<b>≜</b> ALERT	Problems that need to be addressed
♠ NOTE	<u>Potential</u> problems that should be reviewed and corrected, if possible (if not possible, then may ignore)







### **Review Criteria**

- Entered protocol and results information must be consistent with review criteria applied by PRS Reviewers (ClinicalTrials.gov staff)
- Overview of review criteria
  - Logic and internal consistency
  - Apparent validity
  - Meaningful entries
  - Formatting
- ClinicalTrials.gov Review Criteria (DRAFT)
  - Protocol: https://prsinfo.clinicaltrials.gov/ProtocolDetailedReviewItems.pdf
  - Results: https://prsinfo.clinicaltrials.gov/ResultsDetailedReviewItems.pdf


### **Review Comments**


- When record "Reset", the Responsible Party and Record Owner (if different) will receive an email
- Comments can be accessed within each record with the Review Comments link


39


### **Review Comments (cont.)**


- If record reset without public posting, then major review findings must be addressed
  - Edit to address comments: Release record
- Email <u>register@clinicaltrials.gov</u> if questions on content of comments
  - Include NCT Number (or Unique Protocol ID prior to posting) and description of question with any supporting information
  - May also request teleconference

















### **Review Comments - Protocol**

- Insufficient Outcome Measures are the primary reason protocol records are reset
  - Be familiar with the Protocol Review Criteria for Outcome Measure Title, Description, and Time Frame

http://prsinfo.clinicaltrials.gov/ProtocolDetailedReviewItems.pdf


# New Registrations: ClinicalTrials.gov Identifier (NCT Number)

- Records should be available on ClinicalTrials.gov within 2 to 5 business days of Release
- Where to find the ClinicalTrials.gov Identifier (NCT Number)
  - Email: Sent to the Resp. Party and "Record Owner" (if different)
  - PRS Account: Appears in the "ClinicalTrials.gov ID" field
  - ClinicalTrials.gov: Search using Unique Protocol ID; the NCT Number is listed at the top and bottom of the record
- A study is not "registered" until it receives an NCT Number
  - Initial Release Date will be reported on public site
- Some studies will be "reset" without public posting
- Check your PRS Account and the public site to ensure that a study is properly registered

49


# Caveats Regarding Posting at ClinicalTrials.gov


- Responsible Party must ensure that records meet review criteria
  - Responsible parties should assess their records using available review criteria prior to releasing the records
- Posting does **not** ensure that all review criteria were met
- Comments may still be provided "suggesting" improvements
- ClinicalTrials.gov may note issues and request revisions after record posted publicly














## **Identifying Problem Records**

- Data Entry (Record Owner) Issues: e.g.,
  - PRS Review Comments that need to be addressed
  - Record(s) for recruiting studies that have not been updated or verified within the past six months.
- FDAAA 801 issues: e.g.,
  - Record(s) are missing one or more data elements required by FDAAA...
  - Record(s) appear to be overdue for results submission
- Administrator Issues: e.g.,
  - Record ready for Review and Approval
  - Update Not Released

57

### **Problem Records – FDAAA Issues**

- · For Informational Purposes Only
- Determination of whether a trial is subject to FDAAA must be made by the Responsible Party
- How do I get my trial off the report?
  - Provide all FDAAA required data elements
  - Verify accuracy of data for the following data elements:
    - Study Type, Intervention Type, Study Phase, IND/IDE Protocol?, Facility Location(s), Completion Dates – Primary and Study
  - If relevant, submit results, certification or extension request
    - Note: PRS can't detect if trial includes an unapproved product.

### What is an ACT?

- "Applicable Clinical Trials"\* (ACTs) subject to FDAAA are:
  - Interventional studies of drugs, biologics, & devices
  - Not phase 1 (drugs/biologics), not small feasibility (devices)
  - US FDA jurisdiction (e.g., IND/IDE or US site)
  - ACTs initiated after 9/27/07 or if initiated on or before 9/27/07, "ongoing" as of 12/26/07

http://prsinfo.clinicaltrials.gov/ElaborationsOnDefinitions.pdf

59

### **FDAAA Issues Records**

- ClinicalTrials.gov Protocol Data Elements
  - Study Type [Interventional] AND
  - Intervention Type [Drug, Biologic, Device, Radiation or Genetic] AND
  - Study Phase [Not Phase 0 or Phase 1] AND
  - Facility Location(s) [At least 1 US location or locations not specified] OR IND/IDE Protocol? [Yes] AND
  - Primary Completion Date (PCD) [on or after January 2008 or not specified] <u>OR</u> Study Completion Date [on or after January 2008 if PCD not specified] <u>AND</u>
  - Overall Recruitment Status [not Withdrawn]

### **How to Avoid FDAAA Issues**

- Provide all FDAAA data elements (i.e., address all Warnings)
- Ensure data elements used to identify records with potential FDAAA Issues are properly specified
- Use Primary Completion Date to identify studies that may be due for results within the next year
  - Notify Responsible Party at regular intervals


61


62

### **Study Record Process Overview** Create new Release study record study record Data Elements PRS Review PRS Account PRS Automatic NCT Number Validation Rules Assigned Review Criteria Backend Processing 1 – 2 business days Public Access on ClinicalTrials.gov

Public







### **Questions?**

Email register@clinicaltrials.gov at any time!